Meaxin

Imatinib, the active ingredient in Meaxin, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of specific cancers, notably chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumors, targeting malignant cells that rely on BCR‑ABL, c‑KIT, or PDGFR signaling.

GNH USA supplies Meaxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to high‑quality oncology medicines.

Imatinib is indicated for malignancies driven by BCR‑ABL, c‑KIT, or PDGFR tyrosine‑kinase activity. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival in patients with BCR‑ABL‑positive disease. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by targeting the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT–driven tumor growth, leading to disease control in patients with advanced disease.

Imatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Myelosuppression: neutropenia, anemia, or thrombocytopenia. - Cardiac toxicity: rare cases of congestive heart failure or arrhythmias.

When prescribing Imatinib, clinicians should consider several safety measures and monitoring requirements. - Baseline labs: obtain complete blood count, liver function tests, and renal function before initiating therapy. - Hepatic monitoring: repeat liver enzymes regularly, adjust dose if significant elevation occurs. - Cardiac assessment: evaluate cardiac history and monitor for signs of heart failure during treatment. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers that may alter exposure. - Pregnancy and lactation: avoid use in pregnancy; advise effective contraception and discuss risks if breastfeeding. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Imatinib interacts with several agents that can modify its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Imatinib levels and risk severe adverse effects. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower drug exposure, reducing efficacy. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly reduce bioavailability; separate dosing by at least 2 hours. - Warfarin: Imatinib can enhance anticoagulant effect; monitor INR closely. - Vaccines: live attenuated vaccines should be avoided due to potential immunosuppression.